A Randomized, Double-Blind, Placebo Controlled, Phase Ib Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple-Dose Escalation HS-10383 in Healthy Adult Subjects
Latest Information Update: 26 Oct 2023
At a glance
- Drugs HS 10383 (Primary)
- Indications Cough
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 26 Oct 2023 New trial record